<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100926">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02040259</url>
  </required_header>
  <id_info>
    <org_study_id>T4025</org_study_id>
    <nct_id>NCT02040259</nct_id>
  </id_info>
  <brief_title>Trevo® Retriever Registry Post Market Surveillance</brief_title>
  <official_title>Stryker Neurovascular Trevo® Retriever Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Trevo® Retriever Registry is to collect real world performance data of
      the Trevo Retriever which is intended to restore blood flow in the neurovasculature by
      removing thrombus in patients experiencing ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trevo Retriever Registry is a prospective, open-label, consecutive enrollment, multi-center,
      international registry that may enroll a maximum of 300 patients at up to 40 sites
      worldwide. Revascularization status will be assessed at the end of the procedure using the
      modified TICI (Thrombolysis in Cerebral Infarction)score. Additional data collection will
      include:

        1. Day 90 mRS assessment

        2. Day 90 all cause mortality

        3. Neurological deterioration at 24 hours post procedure, defined as a four or more point
           increase in the NIHSS score from the baseline score

        4. Rates of device and procedure related serious adverse events (AEs)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Revascularization status assessment at the end of the Trevo Retriever procedure using the modified TICI score</measure>
    <time_frame>Modified TICI score assess at the end of the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS assessment</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the rate of participants with mRS &lt;/=2  to determine good clinial outcomes at 90 days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the rates of device and procedure related serious adverse events (AEs)</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Assess all cause mortality</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Report if cause of death is device or procedure related.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Mechanical thrombectomy, Trevo Retriever</arm_group_label>
    <description>Mechanical thrombectomy, Trevo Retriever</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Acute ischemic stroke patients who may be referred for mechanical thrombectomy is used to
        removed thrombus in the neurovasculature
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects experiencing acute ischemic stroke who are eligible for restoration of
             blood flow using any approved Trevo Retriever in the neurovasculature to remove
             thrombus

          -  Trevo Retriever is the initial mechanical neuro-thrombectomy device used to remove
             the thrombus

          -  Signed Informed Consent obtained

          -  Subject willing to comply with the protocol follow-up requirements

          -  Anticipated life expectancy of at least 3 months

        Exclusion Criteria:

          -  The subject is participating in another mechanical neuro-thrombectomy device trial or
             any other clinical trial where the study procedure or treatment might confound the
             study end point.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erol Veznedaroglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health System, Trenton, NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Budzik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riverside Methodist Hospital/ Ohio Health Research Institute, Columbus, OH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula P Schmidt, RN</last_name>
    <phone>510.413.2177</phone>
    <email>paula.schmidt@stryker.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joey English, MD</last_name>
      <phone>415-600-1163</phone>
      <email>joeyenglish@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Warren Kim, MD</last_name>
      <phone>415.600.7765</phone>
      <email>kimwt@sutterhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joey English, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Warren Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Miller, MD</last_name>
      <phone>410-328-5112</phone>
      <email>tmiller5@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Tim Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Health System</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08638</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy J Binning, MD</last_name>
      <phone>609-394-6287</phone>
      <email>mbinning@capitalhealth.org</email>
    </contact>
    <investigator>
      <last_name>Mandy J Binning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciaran Powers</last_name>
      <phone>614-293-0689</phone>
      <email>ciaran.powers@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ciaran Powers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital/ Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Budzik</last_name>
      <phone>614-566-1250</phone>
      <email>rbudzik@riversiderad.com</email>
    </contact>
    <contact_backup>
      <last_name>Peter Pema</last_name>
      <phone>614.566.1250</phone>
      <email>ppema@riversiderad.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Budzik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Pema, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qaisar Shah</last_name>
      <phone>215-481-3145</phone>
      <email>qshah@amh.org</email>
    </contact>
    <contact_backup>
      <last_name>Osman Kozak</last_name>
      <phone>215.481.3145</phone>
      <email>okozak@amh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Qaisar Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Osman Kozak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blaise Baxter</last_name>
      <phone>423-778-7234</phone>
      <email>bbaxter27@comcast.net</email>
    </contact>
    <contact_backup>
      <last_name>Steven Quarfordt</last_name>
      <phone>423.778.7234</phone>
      <email>stevedq5@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Blaise Baxter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Quarfordt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Ferrell, MD</last_name>
      <phone>865-712-7210</phone>
      <email>andrewsferrell@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Henry</last_name>
      <phone>865-305-8046</phone>
      <email>jhenry@mc.utmck.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Ferrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kvamme, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare - Memphis Hospitals</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Elijovich, MD</last_name>
      <phone>901-522-7767</phone>
      <email>lelijovich@semmes-murphey.com</email>
    </contact>
    <contact_backup>
      <last_name>Hani Rashed</last_name>
      <phone>901-522-7767</phone>
      <email>hani.rashed@mlh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lucas Elijovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Arthur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>mechanical thrombectomy device</keyword>
  <keyword>Retriever</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
